Development of the research and development facilities Pharma for the development of new radio-nuclides for the targeted oncological and neurologic diagnosis by positron emission tomography (PET) (Q80356): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The project is the development of R & D Synectar Pharma Sp. z o.o.’ facilities for the purpose of implementing the Research Agenda (Annex to the proposal).The project will be carried out in two locations in Kielce (the highest value and the most important part of the project) and in Mszczonów.The success of the research agenda will enable the registration and production in Poland of three inaccessible radiopharmaceuticals in Poland for the del...) |
(Created claim: summary (P836): The subject of the project is the development of R & D facilities Synektik Pharma Sp. z o.o. in order to implement the Research Agenda (an annex to the application). The project will be implemented in two locations, in Kielce (the largest and most important part of the Project) and in Mszczonów. Achieving the research success of the Agenda will allow the registration and production in Poland of three radiopharmaceuticals not yet available in the...) |
||||||||||||||
| Property / summary | |||||||||||||||
The subject of the project is the development of R & D facilities Synektik Pharma Sp. z o.o. in order to implement the Research Agenda (an annex to the application). The project will be implemented in two locations, in Kielce (the largest and most important part of the Project) and in Mszczonów. Achieving the research success of the Agenda will allow the registration and production in Poland of three radiopharmaceuticals not yet available in the country for targeted oncological and neurological diagnostics using Positron Emission Tomography (PET). Two of them will be manufactured on the basis of licences planned to be purchased in the Project (new place of manufacture in the product register) and the third will ultimately be the applicant’s own product. As a result of the project, the Company will increase its R & D expenditures both during and after the shelf life. Cooperation with scientific bodies, including the commissioning of research services and the organisation of joint scientific experiments and publications will also be gradually expanded. (English) | |||||||||||||||
| Property / summary: The subject of the project is the development of R & D facilities Synektik Pharma Sp. z o.o. in order to implement the Research Agenda (an annex to the application). The project will be implemented in two locations, in Kielce (the largest and most important part of the Project) and in Mszczonów. Achieving the research success of the Agenda will allow the registration and production in Poland of three radiopharmaceuticals not yet available in the country for targeted oncological and neurological diagnostics using Positron Emission Tomography (PET). Two of them will be manufactured on the basis of licences planned to be purchased in the Project (new place of manufacture in the product register) and the third will ultimately be the applicant’s own product. As a result of the project, the Company will increase its R & D expenditures both during and after the shelf life. Cooperation with scientific bodies, including the commissioning of research services and the organisation of joint scientific experiments and publications will also be gradually expanded. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The subject of the project is the development of R & D facilities Synektik Pharma Sp. z o.o. in order to implement the Research Agenda (an annex to the application). The project will be implemented in two locations, in Kielce (the largest and most important part of the Project) and in Mszczonów. Achieving the research success of the Agenda will allow the registration and production in Poland of three radiopharmaceuticals not yet available in the country for targeted oncological and neurological diagnostics using Positron Emission Tomography (PET). Two of them will be manufactured on the basis of licences planned to be purchased in the Project (new place of manufacture in the product register) and the third will ultimately be the applicant’s own product. As a result of the project, the Company will increase its R & D expenditures both during and after the shelf life. Cooperation with scientific bodies, including the commissioning of research services and the organisation of joint scientific experiments and publications will also be gradually expanded. (English) / qualifier | |||||||||||||||
point in time: 14 October 2020
| |||||||||||||||
Revision as of 12:11, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of the research and development facilities Pharma for the development of new radio-nuclides for the targeted oncological and neurologic diagnosis by positron emission tomography (PET) |
Project in Poland financed by DG Regio |
Statements
1,548,932.49 zloty
0 references
3,442,072.19 zloty
0 references
45.0 percent
0 references
1 October 2018
0 references
31 December 2019
0 references
SYNEKTIK PHARMA SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
0 references
50°51'14.4"N, 20°36'35.6"E
0 references
Przedmiotem Projektu jest rozwój zaplecza B+R Synektik Pharma Sp. z o.o. w celu realizacji Agendy badawczej (załącznik do wniosku). Projekt realizowany będzie w dwóch lokalizacjach, w Kielcach (największa wartościowo i najistotniejsza część Projektu) oraz w Mszczonowie. Osiągnięcie sukcesu badawczego Agendy umożliwi zarejestrowanie i wytwarzanie w Polsce trzech niedostępnych dotąd w kraju radiofarmaceutyków do celowanej diagnostyki onkologicznej i neurologicznej metodą Pozytonowej Tomografii Emisyjnej (PET). Dwa z nich wytwarzane będą na podstawie planowanych do nabycia w Projekcie licencji (nowe miejsce wytwarzania w rejestrze produktu), a trzeci docelowo jako produkt własny Wnioskodawcy. W wyniku realizacji Projektu Spółka zwiększy nakłady na działalność B+R zarówno w trakcie jak i po okresie trwałości. Stopniowo rozszerzana będzie również nawiązana współpraca z jednostkami naukowymi, w tym zlecanie usług badawczych oraz organizacja wspólnych eksperymentów naukowych i publikacji. (Polish)
0 references
The subject of the project is the development of R & D facilities Synektik Pharma Sp. z o.o. in order to implement the Research Agenda (an annex to the application). The project will be implemented in two locations, in Kielce (the largest and most important part of the Project) and in Mszczonów. Achieving the research success of the Agenda will allow the registration and production in Poland of three radiopharmaceuticals not yet available in the country for targeted oncological and neurological diagnostics using Positron Emission Tomography (PET). Two of them will be manufactured on the basis of licences planned to be purchased in the Project (new place of manufacture in the product register) and the third will ultimately be the applicant’s own product. As a result of the project, the Company will increase its R & D expenditures both during and after the shelf life. Cooperation with scientific bodies, including the commissioning of research services and the organisation of joint scientific experiments and publications will also be gradually expanded. (English)
14 October 2020
0 references
Identifiers
POIR.02.01.00-00-0023/18
0 references